These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33116571)

  • 1. Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety.
    Ni J; Cheng X; Chen J; Guo W; Dai Z
    Onco Targets Ther; 2020; 13():9857-9863. PubMed ID: 33116571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study.
    Wu Y; Li P; Zhu Y; Zhang F; Su L; Ye Y; Huang Y; Zhang M
    Am J Transl Res; 2023; 15(3):1973-1981. PubMed ID: 37056822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer.
    He Y; Zhai A; Qin K; Zhou X; Yu Y; Zhang Z
    Discov Oncol; 2024 Aug; 15(1):383. PubMed ID: 39207632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
    Cui Q; Hu Y; Ma D; Liu H
    Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma.
    She L; Su L; Shen L; Liu C
    Front Oncol; 2021; 11():687564. PubMed ID: 34354945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.
    Liu G; Feng Y; Li J; Deng T; Yin A; Yan L; Zheng M; Xiong Y; Li J; Huang Y; Zhang C; Huang H; Wan T; Huang Q; Lin A; Jiang J; Kong B; Liu J
    EClinicalMedicine; 2022 Dec; 54():101767. PubMed ID: 36583171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
    Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
    Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
    Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
    Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
    Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma.
    Li Q; Su T; Zhang X; Pan Y; Ma S; Zhang L; Zhang X; Gao X
    Cancer Manag Res; 2022; 14():3037-3046. PubMed ID: 36275784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
    Jiang HT; Li W; Zhang B; Gong Q; Qie HL
    Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab.
    Jiang F; Li J; Kong X; Sun P; Qu H
    Front Pharmacol; 2022; 13():973448. PubMed ID: 36238567
    [No Abstract]   [Full Text] [Related]  

  • 13. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
    Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
    Front Oncol; 2022; 12():939343. PubMed ID: 35965587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
    Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
    Front Oncol; 2022; 12():885350. PubMed ID: 35860585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
    Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
    Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis.
    Hong X; Qiu S; Ding B; Xu H; Shen Y
    Ther Adv Med Oncol; 2024; 16():17588359231221336. PubMed ID: 38188470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study.
    Shen W; Jing C; Tian W; Zhang W; Ren Y; Shan B; Wang H
    Int J Gynecol Cancer; 2023 Nov; 33(11):1764-1770. PubMed ID: 37775281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J; Deng YT; Jiang Y
    Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
    Front Oncol; 2022; 12():894835. PubMed ID: 36203439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.
    Yuan M; Zhu Z; Mao W; Wang H; Qian H; Wu J; Guo X; Xu Q
    Front Oncol; 2021; 11():683502. PubMed ID: 34692475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.